<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02504333</url>
  </required_header>
  <id_info>
    <org_study_id>TTD-14-05</org_study_id>
    <nct_id>NCT02504333</nct_id>
  </id_info>
  <brief_title>Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic Adenocarcinoma</brief_title>
  <acronym>SEQUENCE</acronym>
  <official_title>A Phase I/II Study of Nab-paclitaxel (Abraxane) and Gemcitabine Followed by Modified FOLFOX (AG-mFOLFOX) in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of nab-paclitaxel (Abraxane)&#xD;
      and gemcitabine followed by modified FOLFOX (AG-mFOLFOX) in patients with previously&#xD;
      untreated, metastatic pancreatic adenocarcinoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">April 2021</completion_date>
  <primary_completion_date type="Actual">April 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity for the AG-mFOLFOX combination</measure>
    <time_frame>12 weeks</time_frame>
    <description>Primary outcome phase I.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of overall survival al 12 months</measure>
    <time_frame>12 weeks</time_frame>
    <description>Primary outcome phase II</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of overall survival at 6 months</measure>
    <time_frame>54 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of overall survival at 24 months</measure>
    <time_frame>54 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tumor progression</measure>
    <time_frame>54 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>54 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>54 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective radiographic response</measure>
    <time_frame>54 months</time_frame>
    <description>Secondary outcome Phase I and Phase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CA 19-9 biomarker response</measure>
    <time_frame>54 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of this combination (AG-mFOLFOX) using NCI-CTCAE v.4 criteria</measure>
    <time_frame>54 months</time_frame>
    <description>Secondary outcome Phase I and Phase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the Quality of Life of the patients through the EORTC QLQ-C30 and EORTC QLQ-CIPN20 questionnaires</measure>
    <time_frame>54 months</time_frame>
    <description>Secondary outcome Phase I and Phase II</description>
  </secondary_outcome>
  <other_outcome>
    <measure>microRNA expression levels and their correlation with tumour-efficacy parameters</measure>
    <time_frame>54 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Biomarker determination (tissue sample at basal point and blood samples at basal and at the end of treatment). Correlation with treatment response</measure>
    <time_frame>54 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Metastatic Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>AG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nab-Paclitaxel followed by Gemcitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AG-mFOLFOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nab-Paclitaxel followed by Gemcitabine and FOLFOXm at dose levels selected from the phase I trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel</intervention_name>
    <description>Day 1-8-15: Intravenous, 125 mg/m2 over 30 minutes</description>
    <arm_group_label>AG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>Day 1-8-15: Intravenous, 1.000 mg/m2 over 30 minutes</description>
    <arm_group_label>AG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>m-FOLFOX</intervention_name>
    <description>Day 28 according to the dose levels stablished in Phase I</description>
    <arm_group_label>AG-mFOLFOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel</intervention_name>
    <description>Day 1-8-15: Intravenous 30 minutes according to the dose levels stablished in Phase I</description>
    <arm_group_label>AG-mFOLFOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>Day 1-8-15: Intravenous 30 minutes according to the dose levels stablished in Phase I</description>
    <arm_group_label>AG-mFOLFOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically and/or cytologically confirmed pancreatic adenocarcinoma&#xD;
&#xD;
          2. Stage IV disease (metastatic only)&#xD;
&#xD;
          3. No prior systemic therapy for their diagnosis (except in adjuvant setting&gt;six months&#xD;
             previously)&#xD;
&#xD;
          4. ECOG performance status of 0-1&#xD;
&#xD;
          5. At least 18 years of age&#xD;
&#xD;
          6. Evidence of either or both of the following RECIST-defined measurable disease (lesions&#xD;
             that can be accurately measured in at least one dimension with the longest diameter ≥&#xD;
             20mm using conventional techniques or ≥10 mm with spiral CT scan)&#xD;
&#xD;
          7. Female patients must be either surgically sterile or postmenopausal, or if of&#xD;
             childbearing potential must have a negative pregnancy test (serum or urine) prior to&#xD;
             enrollment and agree to use effective barrier contraception during the period of&#xD;
             therapy. Oral, implantable, or injectable contraceptives may be affected by cytochrome&#xD;
             P450 interactions, and are therefore not considered effective for this study. Male&#xD;
             patients must be surgically sterile or must agree to use effective contraception&#xD;
             during the period of therapy. The definition of effective contraception will be based&#xD;
             on the judgment of the investigator.&#xD;
&#xD;
          8. Adequate bone marrow function:&#xD;
&#xD;
               -  ANC ≥ 1500/uL&#xD;
&#xD;
               -  platelet count ≥ 100,000/uL&#xD;
&#xD;
               -  hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          9. Adequate hepatic function:&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 X ULN or until 2mg/dL&#xD;
&#xD;
               -  AST (SGOT) ≤ 2.5 X ULN&#xD;
&#xD;
               -  ALT (SGPT) ≤ 2.5 X ULN&#xD;
&#xD;
         10. Adequate renal function as determined by either:&#xD;
&#xD;
             - Calculated or measured creatinine clearance ≥ 40 mL/min (for calculated creatinine&#xD;
             clearance, Cockroft-Gault equation will be used).&#xD;
&#xD;
         11. Ability to understand the nature of this study protocol and give written informed&#xD;
             consent.&#xD;
&#xD;
         12. Willingness and ability to comply with scheduled visits, treatment plans, laboratory&#xD;
             tests, and other study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of other disease, metabolic dysfunction, physical examination finding, or&#xD;
             clinical laboratory finding giving reasonable suspicion of a disease or condition&#xD;
             that, in the opinion of the investigator, renders the subject at high risk from&#xD;
             treatment complications or might affect the interpretation of the results of the&#xD;
             study.&#xD;
&#xD;
          2. Presence of central nervous system or brain metastases.&#xD;
&#xD;
          3. Life expectancy &lt; 12 weeks&#xD;
&#xD;
          4. Pregnancy (positive pregnancy test) or lactation.&#xD;
&#xD;
          5. Pre-existing sensory neuropathy &gt; grade 1.&#xD;
&#xD;
          6. Clinically significant cardiac disease (e.g. congestive heart failure, symptomatic&#xD;
             coronary artery disease and cardiac arrhythmias not well controlled with medication)&#xD;
             or myocardial infarction within the last 12 months.&#xD;
&#xD;
          7. Major surgery within 4 weeks of the start of study treatment, without complete&#xD;
             recovery.&#xD;
&#xD;
          8. Prior malignancy except for adequately treated basal cell skin cancer, in situ&#xD;
             cervical cancer, adequately treated Stage I or II cancer from which the patient is&#xD;
             currently in complete remission, or any other form of cancer from which the patient&#xD;
             has been disease-free for 5 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfredo Carrato, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario Ramón y Cajal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmen Guillén, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario Ramón y Cajal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spanish Cooperative for Digestive Tumour Therapy (TTD)</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.ttdgroup.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 20, 2015</study_first_submitted>
  <study_first_submitted_qc>July 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2015</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic pancreatic adenocarcinoma</keyword>
  <keyword>Nab-paclitaxel</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>modified FOLFOX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

